Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow QURE by emailGet an email when QURE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QURE, unsubscribe in one click. Privacy
📣 What QURE Says Is Next
first half of 2027 · “The Company expects to present updated results from the Phase I/IIa study in the first half of 2027.”
Company press release, Jul 29, 2026 · SEC filing
second half of 2026 · “The Company is also actively pursuing additional regulatory pathways in international markets for potential registration of AMT-130 and expects to provide further updates in the second half of 2026. About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results.”
Company press release, Apr 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full QURE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QURE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.